Gaps in Treatment Among Users of Osteoporosis Medications: The Dynamics of Noncompliance

American Journal of Medicine

Volumn 120, Issue 3, 2007, Pages 251-256

  Brookhart, M Alan ^a   Avorn, Jerry ^a   Katz, Jeffrey N ^a   Finkelstein, Joel S ^a   Arnold, Marilyn ^a   Polinski, Jennifer M ^a   Patrick, Amanda R ^a   Mogun, Helen ^a   Solmon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adherence; Drug holiday; Medication compliance; Osteoporosis; Persistence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; RALOXIFENE;

AGED; ARTICLE; BONE DENSITY; BONE MINERAL; COMORBIDITY; DRUG USE; FEMALE; HIP FRACTURE; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; OSTEOPOROSIS; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; RADIUS FRACTURE; SPINE FRACTURE; SURVIVAL; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; ATTITUDE TO HEALTH; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; COHORT STUDIES; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RALOXIFENE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 33846814166     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.03.029     Document Type: Article

References (23)

1. Haynes R.B., Taylor W.D., and Sackett D.L. Compliance in Health Care (1979), The Johns Hopkins University Press, Baltimore, MD
2. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
3. Hughes D.A., Bagust A., Haycox A., and Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 10 (2001) 601-615
4. Stephenson J. Noncompliance may cause half of antihypertensive drug "failures". JAMA 282 (1999) 313-314
5. McDonald H.P., Garg A.X., and Haynes R.B. Interventions to enhance patient adherence to medication prescriptions: scientific review. [see comment] [erratum appears in JAMA. 2003 Jun 25;289:3242]. JAMA 288 (2002) 2868-2879
6. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications [update of Cochrane Database Syst Rev. 2000(2):CD000011; PMID: 10796686]. Cochrane Database Syst Rev. 2002(2):CD000011.
7. Sabate E. Adherence to long-term therapies: evidence for action. World Health Organization [Web report] (2005). http://www.who.int/chronic_conditions/en/adherence_report.pdf Available at: http://www.who.int/chronic_conditions/en/adherence_report.pdf. Accessed August 10
8. Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med 165 (2005) 2414-2419
9. Clowes J.A., Peel N.F., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 1117-1123
10. Ellis J.J., Erickson S.R., Stevenson J.G., Bernstein S.J., Stiles R.A., and Fendrick A.M. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 19 (2004) 638-645
11. Yang C.C., Jick S.S., and Testa M.A. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol 56 (2003) 84-91
12. Grant R.W., O'Leary K.M., Weilburg J.B., Singer D.E., and Meigs J.B. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 164 (2004) 2343-2348
13. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in use of statin therapy in elderly patients [see comment]. JAMA 288 (2002) 455-461
14. Chapman R.H., Benner J.S., Petrilla A.A., et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165 (2005) 1147-1152
15. Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. Clin Pharmacol Ther 67 (2000) 331-334
16. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 32 (1997) 345-356
17. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Cox D.R. Regression models and lifetables. J R Stat Soc Ser B (1972) 187-220
19. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133 (1991) 144-153
20. Wang P.S., Schneeweiss S., Glynn R.J., Mogun H., and Avorn J. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol 14 (2004) 296-303
21. SAS, Version 9.1 [computer program]. Cary, NC: SAS Institute Inc.; 2003.
22. Jachna C.M., Shireman T.I., Whittle J., Ellerbeck E.F., and Rigler S.K. Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers. J Am Geriatr Soc 53 (2005) 1275-1281
23. Gupta G., and Aronow W.S. Underuse of procedures for diagnosing osteoporosis and of therapies for osteoporosis in older nursing home residents. J Am Med Dir Assoc 4 (2003) 200-202